Instauration d'une insulinothérapie chez le patient diabétique de type 2 en médecine générale: Comparaison de l’étude belge InsuStar avec quelques études françaises et internationales

Scheen, André

doi:10.1016/S1957-2557(16)30121-3

Article (Scientific journals)

Instauration d'une insulinothérapie chez le patient diabétique de type 2 en médecine générale: Comparaison de l’étude belge InsuStar avec quelques études françaises et internationales

Scheen, André

2016 • In Médecine des Maladies Métaboliques, 10 (4), p. 334-340

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/216151

DOI
10.1016/S1957-2557(16)30121-3

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2016 MMM Instauration d’une insulinothérapie chez D2.pdf

Publisher postprint (91.75 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Type 2 diabetes; Article

Abstract :

[en] Initiating insulin therapy is often considered as a challenge in general practice, thus leading to a delay in the shift to insulin. We compare the results of the observational prospective Belgian study InsuStar with those of several French and international studies. In most studies, initiating insulin therapy is proposed in patients with glycated hemoglobin (HbA1c) around 9% (75 mmol/mol). The initiation of insulin therapy, in most cases using basal insulin (NPH, or glargine), is associated with a mean HbA1c reduction of about 1.5%, but only around one third of the patients reach a target HbA1c level <7% (53 mmol/mol), which should promote further intensification of treatment. The risk of hypoglycemia is low, and patient's acceptance of insulin injection is usually good. These results should encourage general practitioners to initiate insulin therapy at an earlier stage in patients with insufficiently controlled type 2 diabetes on oral agents. © 2016 Elsevier Masson SAS

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Instauration d'une insulinothérapie chez le patient diabétique de type 2 en médecine générale: Comparaison de l’étude belge InsuStar avec quelques études françaises et internationales

Alternative titles :

[en] Initiating and intensifying insulin therapy in general practice: InsuStar, an observational Belgian prospective study in type 2 diabetes

Publication date :

2016

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson SAS

Volume :

Issue :

Pages :

334-340

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 17 November 2017

Statistics

Number of views

64 (2 by ULiège)

Number of downloads

474 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

[1] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
[2] Charbonnel, B., Penfornis, A., Varroud-Vial, M., et al. Insulin therapy for diabetes mellitus: treatment regimens and associated costs. Diabetes Metab 38 (2012), 156–163.
[3] Philips, J.C., Scheen, A.J., Inertie clinique dans la prise en charge du patient diabétique de type 2: quelles solutions proposer ?. Rev Med Liège 65 (2010), 318–325.
[4] Avignon, A., Attali, C., Sultan, A., et al. Clinical inertia: viewpoints of general practitioners and diabetologists. Diabetes Metab 38:Suppl.3 (2012), S53–S58.
[5] Aujoulat, I., Jacquemin, P., Rietzschel, E., et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract 5 (2014), 141–147.
[6] Hanefeld, M., Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. Diabetes Metab 40 (2014), 391–399.
[7] Home, P., Riddle, M., Cefalu, W.T., et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges?. Diabetes Care 37 (2014), 1499–1508.
[8] Ng, C.J., Lai, P.S., Lee, Y.K., et al. Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review. Int J Clin Pract 69 (2015), 1050–1070.
[9] Nobels, F., Mathieu, C., Scheen, A.J., Instauration et optimisation d'une insulinothérapie dans le diabète de type 2 (DT2) en médecine générale: résultats d'une étude observationnelle nationale belge. Diabetes Metab, 41(Suppl 1), 2015 A120 [Abstract P342].
[10] Scheen, A.J., Mathieu, C., Nobels, F., Instauration et optimisation d'une insulinothérapie en médecine générale: InsuStar, une étude observationnelle prospective belge dans le diabète de type 2. Rev Med Liège 70 (2015), 423–431.
[11] Penfornis, A., San-Galli, F., Cimino, L., Huet, D., Current insulin therapy in patients with type 2 diabetes: results of the ADHOC survey in France. Diabetes Metab 37 (2011), 440–445.
[12] Vergès, B., Brun, J.M., Tawil, C., et al. Strategies for insulin initiation: insights from the French LIGHT observational study. Diabetes Metab Res Rev 28 (2012), 97–105.
[13] Charles, M.A., Chartier, F., Bonnard, C., et al. Instauration de l'insulinothérapie chez les diabétiques de type 2 en France: données de l’étude INSTIGATE. Médecine des maladies Métaboliques 5 (2011), 189–198.
[14] Liebl, A., Jones, S., Benroubi, M., et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin 27 (2011), 887–895.
[15] Halimi, S., Balkau, B., Attali, C., et al. Therapeutic management of orally treated type 2 diabetic patients, by French general practitioners in 2010: the DIAttitude Study. Diabetes Metab 38:Suppl.3 (2012), S36–S46.
[16] Kostev, K., Rathmann, W., Influence of macro- and microvascular comorbidity on time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany, France, and UK. Prim Care Diabetes 7 (2013), 167–171.
[17] Reach, G., Le Pautremat, V., Gupta, S., Determinants and consequences of insulin initiation for type 2 diabetes in France: analysis of the National Health and Wellness Survey. Patient Prefer Adherence 7 (2013), 1007–1023.
[18] Kerlan, V., Vergès, B., Tawil, C., et al. Insulin initiation in elderly patients with type 2 diabetes in France: a subpopulation of the LIGHT study. Curr Med Res Opin 28 (2012), 503–511.
[19] Balkau, B., Bouée, S., Avignon, A., et al. Type 2 diabetes treatment intensification in general practice in France in 2008-2009: the DIAttitude Study. Diabetes Metab 38:Suppl.3 (2012), S29–S35.
[20] Meneghini, L.F., Dornhorst, A., Sreenan, S., PREDICTIVE Study Group. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. Curr Med Res Opin 25 (2009), 1029–1035.
[21] Home, P., El Naggar, N., Khamseh, M., et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract 94 (2011), 352–363.
[22] Valensi, P., Benroubi, M., Borzi, V., et al. IMPROVE Study Group Expert Panel. The IMPROVE study—a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 62 (2008), 1809–1819.
[23] Blak, B.T., Smith, H.T., Hards, M., et al. A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care. Diabet Med 29 (2012), e191–e198.
[24] Home, P.D., Dain, M.P., Freemantle, N., et al. Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Res Clin Pract 108 (2015), 350–359.
[25] Kim, S.S., Kim, I.J., Kim, Y.K., et al. Insulin initiation in insulin-naive Korean type 2 diabetic patients inadequately controlled on oral antidiabetic drugs in real-world practice: the Modality of Insulin Treatment Evaluation Study. Diabetes Metab J 39 (2015), 481–488.
[26] Ji, L., Tsai, S.T., Lin, J., Bhambani, S., National variations in comorbidities, glycosylated hemoglobin reduction. Diabetes Ther and insulin dosage in Asian patients with type 2 diabetes:, 2015, the FINE-Asia Registry Oct 14 [Epub ahead of print].
[27] Seufert, J., Pegelow, K., Bramlage, P., Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Vasc Health Risk Manag 9 (2013), 711–717.
[28] Owens, D.R., Traylor, L., Dain, M.P., Landgraf, W., Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials. Diabetes Res Clin Pract 106 (2014), 264–274.
[29] Kostev, K., Dippel, F.W., Rathmann, W., Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis. Diabetes Metab Syndr Obes 8 (2015), 45–48.
[30] Bhattacharya, R., Zhou, S., Wei, W., et al. A real-world study of the effect of timing of insulin initiation on outcomes in older Medicare beneficiaries with type 2 diabetes mellitus. J Am Geriatr Soc 63 (2015), 893–901.
[31] Balkau, B., Calvi-Gries, F., Freemantle, N., et al. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study. Diabetes Res Clin Pract 108 (2015), 432–440.
[32] Levin, P., Zhou, S., Durden, E., et al. Clinical and economic outcomes associated with the timing of initiation of basal insulin in patients with type 2 diabetes mellitus previously treated with oral antidiabetes drugs. Clin Ther 38 (2016), 110–121.
[33] Fonseca, V., Gill, J., Zhou, R., Leahy, J., An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 13 (2011), 814–822.
[34] Liebl, A., Jones, S., Goday, A., et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther, 3, 2012, 9.
[35] Polinski, J.M., Connolly, J.G., Curtis, B.H., et al. Patterns and trends in insulin intensification among patients with type 2 diabetes: a systematic review. Prim Care Diabetes 8 (2014), 101–109.
[36] Home, P.D., Fritsche, A., Schinzel, S., Massi-Benedetti, M., Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 12 (2010), 772–779.
[37] Peyrot, M., Rubin, R.R., Lauritzen, T., et al. International DAWN Advisory Board. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes. Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005), 2673–2679.
[38] Aujoulat, I., Jacquemin, P., Hermans, M.P., et al. Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium. BMC Fam Pract, 16, 2015, 13.
[39] Peyrot, M., Barnett, A.H., Meneghini, L.F., Schumm-Draeger, P.M., Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 29 (2012), 682–689.
[40] Cariou, B., Fontaine, P., Eschwège, E., et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab 41 (2015), 116–125.
[41] Peene, B., D'Hooge, D., Vandebrouck, T., Mathieu, C., Patient-reported frequency, awareness and patient-physician communication of hypoglycaemia in Belgium. Acta Clin Belg 69 (2014), 439–445.
[42] Xie, L., Wei, W., Pan, C., Baser, O., Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. J Med Econ 16 (2013), 1137–1145.
[43] Reach, G., Consoli, S.M., Halimi, S., et al. The multinational second Diabetes, Attitudes. Wishes and Needs study: results of the French survey. Patient Prefer Adherence 9 (2015), 289–297.
[44] Bennett, H., McEwan, P., Bergenheim, K., Gordon, J., Assessment of unmet clinical need in type 2 diabetic patients on conventional therapy in the UK. Diabetes Ther 5 (2014), 567–578.
[45] Khunti, K., Nikolajsen, A., Thorsted, B.L., et al. Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab 18 (2016), 401–409.
[46] Sunaert, P., Willems, S., Feyen, L., et al. Engaging GPs in insulin therapy initiation: a qualitative study evaluating a support program in the Belgian context. BMC Fam Pract, 15, 2014, 144.
[47] Manski-Nankervis, J.A., Blackberry, I., Young, D., et al. Relational coordination amongst health professionals involved in insulin initiation for people with type 2 diabetes in general practice: an exploratory survey. BMC Health Serv Res, 14, 2014, 515.
[48] Haute Autorité de Santé (HAS). Guide parcours de soins. Diabète de type 2 de l'adulte. Saint-Denis La Plaine, France: Haute Autorité de Santé mars 2014. http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-04/guide_pds_diabete_t_3_web.pdf.